The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally.
metaLinear offers a fast track to highly validated drug targets and lead compounds, some of which will be available for licensing. Our focus is on antibiotics/antibiotic resistance. Our proven technology manipulates proteins inside living cells, reaching the >90% of biology inaccessible to siRNA or CAS/Crispr.
metaLinear was established in November 2016 and began operating from the Biohub at Alderley Park in Cheshire from March 2017. Operated by life science incubation specialist, The BioCity Group, Biohub supports the creation and growth of successful life science companies including Redx, Blueberry Therapeutics and the Anti-Microbial Research Centre.
Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, we pursue targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, we are focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas we aim to develop drugs whose profile suggests they will be best in class, if not first in class.
Silence Therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells.
Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.